Company Overview
| Stock Name | Hansoh Pharma |
|---|---|
| Stock Code | 03692 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是為數不多的以研發為驅動的中國製藥公司之一,在中樞神經系統疾病、抗腫瘤、抗感染及糖尿病等領域擁有廣泛、多元化及領先的藥物組合,並專注於消化道及心血管治療領域。 |
| Listing Date | 2019-06-14 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇連雲港經濟技術開發區東晉路9號(郵編:222069) |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.hspharm.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 14.26 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-05-31 to 2019-06-05 |
| Global Offering Shares | 551,280,000 shares |
| HK Public Offer Shares (Initial) | 38,590,000 shares (7.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 512,690,000 shares (93.0%) |
| Offer Ratio | ~7.0% |
| Total Shares Post-IPO | 5,705,919,200 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 34.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 7,861,252,800 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 208.22B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣19.030億元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 214,900,000 |
| Listing Expenses / Funds Raised | ~2.73% |
| Total Pre-IPO Investment | 248,581,849美元(相當於人民幣1,682,278,000元) |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 5,432,960 | 6,185,537 | 7,722,278 |
| Cost of sales | -397,279 | -455,171 | -603,100 |
| Gross profit | 5,035,681 | 5,730,366 | 7,119,178 |
| Other income and gains, net | 85,811 | 93,230 | 77,953 |
| Selling and distribution expenses | -2,378,040 | -2,704,200 | -3,208,680 |
| Administrative expenses | -537,972 | -614,075 | -790,158 |
| Operating profit | 1,807,689 | 1,932,791 | 2,309,325 |
| Net finance costs | -3,411 | ||
| Profit before tax | 1,804,278 | 1,932,791 | 2,309,325 |
| Income tax expense | -328,244 | -337,318 | -406,277 |
| Profit for the year | 1,476,034 | 1,595,473 | 1,903,048 |
| Profit attributable to owners | 1,476,034 | 1,595,473 | 1,903,048 |
Balance Sheet
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Cash and cash equivalents | 208,699 | 266,444 | 964,831 |
| Trade and bills receivables | 1,723,535 | 2,192,518 | 2,645,207 |
| Inventories | 353,051 | 439,355 | 479,664 |
| Total current assets | 3,463,699 | 4,417,867 | 6,684,185 |
| Total assets | 4,820,951 | 5,874,048 | 8,414,371 |
| Total current liabilities | 1,811,964 | 1,227,674 | 4,503,785 |
| Total liabilities | 1,846,613 | 1,355,358 | 5,946,473 |
| Total equity | 2,974,338 | 4,518,690 | 2,467,898 |
| Equity attributable to owners | 2,974,337 | 4,518,689 | 2,467,897 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Net cash from operating activities | 1,246,507 | 1,402,252 | 2,072,227 |
| Net cash from investing activities | 829,538 | -614,271 | -1,388,744 |
| Depreciation of PP&E | 115,358 | 131,382 | 148,624 |
| Amortisation of intangible assets | 3,679 | 3,964 | 7,641 |
| Purchase of PP&E | -238,926 | -256,346 | -381,378 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 19.5 |
|---|---|
| First Day Open | HK$ 16.3 |
| First Day Change | 36.75% |
| First Day Volume | 138363000.0 |
| First Day Turnover | 2452210000.0 |
| Use of Proceeds | 1、所得款項凈額約45%或3,438百港元用于研發(包括我們現有及未來的國內及海 外藥物開發項目)、擴充我們的研發團隊及于研發技術的投資;
2、約25%或1,910百港元用于生產體系,建設新生產線,升級現有生產設施并提 高其自動化水平;
3、約20%或1,528百港元用于銷售及學術推廣,以配合新產品上市,尤其是四種 將自2019年至2020年上市的創新藥;
4、余款約10%或764百港元將用于撥付我們的營運資金及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (5)
Joint Bookrunners (6)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Ally Bridge LB Healthcare Master Fund Limited | 313,976,680 HKD | — | 3.99% | — | 6 months | 2019-12-14 |
| 2 | Boyu Capital Opportunities Master Fund | 470,950,760 HKD | — | 5.99% | — | 6 months | 2019-12-14 |
| 3 | Cormorant Asset Management, LP | 196,217,600 HKD | — | 2.50% | — | 6 months | 2019-12-14 |
| 4 | GIC Private Limited | 549,466,320 HKD | — | 6.99% | — | 6 months | 2019-12-14 |
| 5 | Hillhouse Funds | 228,758,920 HKD | — | 2.91% | — | 6 months | 2019-12-14 |
| 6 | Prime Capital Funds | 313,976,680 HKD | — | 3.99% | — | 6 months | 2019-12-14 |
| 7 | Vivo Funds | 156,974,080 HKD | — | 2.00% | — | 6 months | 2019-12-14 |
| 8 | Worldwide Healthcare Trust PLC | 313,976,680 HKD | — | 3.99% | — | 6 months | 2019-12-14 |
| 9 | 上海医药(香港)投资有限公司 | 156,974,080 HKD | — | 2.00% | — | 6 months | 2019-12-14 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 鍾慧娟 | — |
| Company Secretary | 鍾勝利、李昕穎 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Stellar Infinity緊隨全球發售完成後持股約68.35%,連同Sunrise Investment、Sunrise Trust受託人、孫小姐及鍾女士被視為控股股東;Apex Medical持股約16.65%,由岑均達先生全資擁有。 |
|---|




